ERS 2026: Brensocatib cuts NCFB exacerbations in NTM history patients
RegulatoryapprovedBrensocatibPositive
AI Analysis
Summary
Brensocatib, which received FDA approval in August 2025 as the first approved therapy for non-cystic fibrosis bronchiectasis, demonstrated efficacy in reducing exacerbations in patients with NTM history according to ERS 2026 presentation data.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
FDA approval for first therapy for NCFB in August 2025
Importance:8/10
Sentiment:
0.80
FDA approvalNCFBbrensocatibrespiratoryfirst-in-classERS 2026
Related Companies
Read the original article
Published by Clinical Trials Arena on September 10, 2026 4:35 PM